Publications
194
Citations
3,955
Est. group size
—
Recurring co-author estimate
Active years
61
Publishing since 1966
Richard L. Carpenter studies the molecular biology of cancer, with a focus on the signaling pathways and transcription factors that drive tumors such as ovarian, uterine, and triple-negative breast cancers. The work uses laboratory and mouse models to understand how genes like MYC and transcription factors like tGLI1 and STAT3 promote cancer growth and treatment resistance, and to identify potential therapeutic targets. Heat shock proteins (stress-response proteins in cells) are another recurring theme in this research.
Publication activity has grown substantially over the past decade, peaking sharply in 2023-2024.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- The 13th International Symposium on Heat Shock Proteins in Biology, Medicine, and the Environment: Honoring legacy, celebrating scientific advances, and fostering collaboration
Cell Stress and Chaperones · 2026
- Abstract 1416: Defining the mechanisms of cancer specific transcription factor, tGLI1
Cancer Research · 2025
- Supplementary Figure 1 from MYC is Sufficient to Generate Mid-Life High-Grade Serous Ovarian and Uterine Serous Carcinomas in a p53-R270H Mouse Model
2025
- Supplementary Figure 6 from MYC is Sufficient to Generate Mid-Life High-Grade Serous Ovarian and Uterine Serous Carcinomas in a p53-R270H Mouse Model
2025
- Supplementary Figure 2 from MYC is Sufficient to Generate Mid-Life High-Grade Serous Ovarian and Uterine Serous Carcinomas in a p53-R270H Mouse Model
2025
- Supplementary Figure 4 from MYC is Sufficient to Generate Mid-Life High-Grade Serous Ovarian and Uterine Serous Carcinomas in a p53-R270H Mouse Model
2025
- Supplementary Table 1 from MYC is Sufficient to Generate Mid-Life High-Grade Serous Ovarian and Uterine Serous Carcinomas in a p53-R270H Mouse Model
2025
- Supplementary Figure 7 from MYC is Sufficient to Generate Mid-Life High-Grade Serous Ovarian and Uterine Serous Carcinomas in a p53-R270H Mouse Model
2025
- Supplementary Figure 5 from MYC is Sufficient to Generate Mid-Life High-Grade Serous Ovarian and Uterine Serous Carcinomas in a p53-R270H Mouse Model
2025
- Supplementary Figure 3 from MYC is Sufficient to Generate Mid-Life High-Grade Serous Ovarian and Uterine Serous Carcinomas in a p53-R270H Mouse Model
2025
- Editor’s Note: Truncated Glioma-Associated Oncogene Homolog 1 (tGLI1) Mediates Mesenchymal Glioblastoma via Transcriptional Activation of CD44
Cancer Research · 2024
- Figure 3 from MYC is Sufficient to Generate Mid-Life High-Grade Serous Ovarian and Uterine Serous Carcinomas in a p53-R270H Mouse Model
2024
- Figure 5 from MYC is Sufficient to Generate Mid-Life High-Grade Serous Ovarian and Uterine Serous Carcinomas in a p53-R270H Mouse Model
2024
- Figure 2 from MYC is Sufficient to Generate Mid-Life High-Grade Serous Ovarian and Uterine Serous Carcinomas in a p53-R270H Mouse Model
2024
- Figure 4 from MYC is Sufficient to Generate Mid-Life High-Grade Serous Ovarian and Uterine Serous Carcinomas in a p53-R270H Mouse Model
2024
- Cancer Research×17
- Oncogene×6
- bioRxiv (Cold Spring Harbor Laboratory)×5
- Cell Stress and Chaperones×3
- PMC×3
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile